FSD Pharma Reports Positive Phase-1 Results for Lucid-21-302 at ACTRIMS 2024

Biopharmaceutical firm FSD Pharma Inc., listed on NASDAQ, CSE, and FRA, has announced its involvement in the ACTRIMS 2024 Forum, which took place from February 29 to March 2 in West Palm Beach, Florida. The company, focused on developing a range of innovative assets and biotech solutions for various disorders, presented findings from a Phase-1 clinical trial of its compound Lucid-21-302, intended for the treatment of Multiple Sclerosis (MS). The study, conducted on healthy volunteers, demonstrated that the compound was safe and well-tolerated within a dose range of 50-300 mg, with no significant adverse events reported. The drug also showed proportionality in drug exposure to the dose and good oral absorption.
Lucid-21-302 is a novel, non-immunomodulatory, neuroprotective compound with a distinct mechanism for treating MS, designed to prevent demyelination, a common cause of MS and other neurodegenerative diseases. The company's presentation was held during the first poster session of the ACTRIMS Forum and is accessible on the FSD Pharma website under the "For Investors" section.
Dr. Andrzej Chruscinski, VP for Scientific and Clinical Affairs at FSD Pharma, expressed enthusiasm about sharing the positive results with the global MS community and the company's commitment to advancing therapies for MS treatment. FSD Pharma, through its subsidiary Lucid Psycheceuticals Inc., is dedicated to the research and development of Lucid-MS, a patented entity that has shown promise in preclinical models for preventing and reversing myelin degradation. The company has also licensed a natural formulation, unbuzzd™, to Celly Nutrition Corp. for use in the consumer sector and continues to develop novel treatments for alcohol misuse disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!